Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

Concurrent use of nimotuzumab with CRT/RT is safe and provides long-term survival benefit.